TY - JOUR T1 - Predicting missed health care visits during the COVID-19 pandemic using machine learning methods: Evidence from 55,500 individuals from 28 European Countries JF - medRxiv DO - 10.1101/2022.03.01.22271611 SP - 2022.03.01.22271611 AU - Anna Reuter AU - Šime Smolić AU - Till Bärnighausen AU - Nikkil Sudharsanan Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/03/04/2022.03.01.22271611.abstract N2 - Background The COVID-19 pandemic has led many individuals to miss essential care. Machine-learning models that predict which patients are at greatest risk of missing care visits can help health administrators prioritize retentions efforts towards patients with the most need. Such approaches may be especially useful for efficiently targeting interventions for health systems overburdened by the COVID-19 pandemic.Methods We compare the performance of four machine learning algorithms to predict missed health care visits based on common patient characteristics available to most health care providers. We use data from 55,500 respondents of the Survey of Health, Ageing and Retirement in Europe (SHARE) COVID-19 survey (June – September 2020) in conjunction with longitudinal data from waves 1-8 (April 2004 – March 2020). We use stepwise selection, group lasso, random forest and neural network algorithms and employ 5-fold cross-validation to test the prediction accuracy, sensitivity, and specificity of the selected models.Findings Within our sample, 15.5% of the respondents reported any missed essential health care visit due to the COVID-19 pandemic. All four machine learning methods perform similarly in their predictive power. When classifying all individuals with a predicted probability for missed care above 17% as at risk of a missed visit, they correctly identify between 41% and 53% of the respondents at risk, while correctly identifying between 74% and 64% of the individuals not at risk. We find that the sensitivity and specificity of the models are strongly related to the risk threshold used to classify individuals; thus, the models can be calibrated depending on users’ resource constraints and targeting approach. All models had an area under the curve around 0.62, indicating that they outperform random prediction.Interpretation Pandemics such as COVID-19 require rapid and efficient responses to reduce disruptions in health care. Based on characteristics available to health insurance providers, machine learning algorithms can be used to efficiently target efforts to reduce missed essential care.Funding Research in this article is a part of the European Union’s H2020 SHARE-COVID19 project (Grant Agreement No. 101015924).Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch in this article is a part of the European Union's H2020 SHARE-COVID19 project (Grant Agreement No. 101015924).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SHARE study was approved by the Ethics Committee at the University of Mannheim (waves 1‐4) and by the Ethics Council of the Max‐Planck‐Society (waves 5‐8). Additionally, country-specific ethics committees or institutional review boards approved implementations of SHARE in the participating countries. All study participants provided informed consentI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study can be retrieved from the SHARE data repository (http://www.share-project.org/data-access.html). Code for replication is available upon reasonable request to the authors. http://www.share-project.org/data-access.html ER -